Seeking Alpha

Biotech Analysis Central Model 10+ Portfolio Old Pick#17 And Removed: Tempest Therapeutics; Phase 3 Study May Proceed TPST-1120, TPST-1495 Data 2025 And Catalysts

The next article I wanted to discuss for the Biotech Analysis Central Model 10+ Portfolio Old Pick #17 is a biotech by the name of Tempest Therapeutics (TPST). I want to state that I have chosen to ...
Seeking Alpha

Biotech Analysis Central Model 10+ Portfolio Pick#17: Tempest Therapeutics; Phase 3 Trial Initiation Amezalpat 2024/2025, TPST-1495 Data For Endometrial Cancer 2nd Half Of 2024 ...

The next article I wanted to discuss for the Biotech Analysis Central Model 10+ Portfolio Pick #17 is a biotech by the name of Tempest Therapeutics (TPST). The last time I spoke about this biotech, it ...